{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced\/Metastatic Non-Squamous Non-Small Cell Lung Cancer","item":"https:\/\/www.regionalcancercare.org\/trials\/a-phase-2-open-label-randomized-global-study-of-three-telisotuzumab-vedotin-regimens-in-subjects-with-previously-treated-c-met-overexpressing-egfr-wildtype-locally-advanced-metastatic-non-squamou-2\/#breadcrumbitem"}]}